HUMIRA® 40 mg Syringe 0.8 mL for Subcutaneous Injection Protocol for Special Investigation on Long-Term Administration Ulcerative Colitis
Phase of Trial: Phase IV
Latest Information Update: 15 May 2019
Price : $35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors AbbVie
- 31 Aug 2018 Biomarkers information updated
- 07 Mar 2018 Status changed from active, no longer recruiting to completed.
- 20 Oct 2017 Planned End Date changed from 31 Mar 2018 to 15 Feb 2018.